Aptevo Therapeutics Inc (APVO)vsargenx NV ADR (ARGX)
APVO
Aptevo Therapeutics Inc
$4.43
+4.86%
HEALTHCARE · Cap: $7.12M
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
APVO
Avoid31
out of 100
Grade: F
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+100.0%
Fair Value
$52755.76
Current Price
$4.42
$52751.33 discount
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : APVO
The strongest argument for APVO centers on Price/Book, Debt/Equity.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bear Case : APVO
The primary concerns for APVO are EPS Growth, Market Cap, Profit Margin.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
APVO profiles as a value stock while ARGX is a growth play — different risk/reward profiles.
APVO carries more volatility with a beta of 1.43 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 31/100), backed by strong 30.5% margins and 73.0% revenue growth. APVO offers better value entry with a 100.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aptevo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?